Secukinumab Effective for Moderate/Severe Scalp Psoriasis

Share this content:
Secukinumab Effective for Moderate/Severe Scalp Psoriasis
Secukinumab Effective for Moderate/Severe Scalp Psoriasis

FRIDAY, Sept. 29, 2017 (HealthDay News) -- Secukinumab is safe and effective as a treatment for patients with extensive moderate-to-severe scalp psoriasis, according to a study published in the October issue of the Journal of the American Academy of Dermatology.

Jerry Bagel, M.D., from the Psoriasis Treatment Center of Central New Jersey in East Windsor, and colleagues conducted a 24-week, double-blind, phase 3b study in which 102 patients were randomized to subcutaneous secukinumab (300 mg) or placebo at baseline; weeks 1, 2, and 3; and then every four weeks from week 4 to 20.

The researchers found that at week 12, 90 percent improvement of the Psoriasis Scalp Severity Index score was seen in 52.9 percent of the secukinumab group versus 2 percent of the placebo group. In addition, Investigator's Global Assessment modified 2011 scalp responses of 0 or 1 were 56.9 percent and 5.9 percent, respectively, with secukinumab and placebo. Significantly more patients achieved complete clearance of scalp psoriasis at week 12 with secukinumab 300 mg compared with placebo (35.3 percent versus 0 percent. The safety of secukinumab was consistent with other phase 3 studies.

"Secukinumab is efficacious and well-tolerated for patients with extensive moderate-to-severe scalp psoriasis," conclude the authors.

Several authors disclosed financial ties to pharmaceutical companies, including Novartis Pharmaceuticals, which funded the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »